CTS-21166, an experimental drug to treat Alzheimer's disease, began the first phase of human clinical trials this week.
"Millions of people suffer from this devastating disease and treatment options are very limited," said Arun Ghosh, a Purdue professor who led the creation of the treatment molecule. "Current drugs manage the symptoms, but this could be the first disease-modifying therapy. It may be able to prevent and reverse the disease."